Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
News|Articles|January 9, 2026
The top stories in glaucoma to enter the new year with
Author(s)Jordana Joy, Editor
New clinical data and trial updates closed out 2025.
Advertisement
Advertisement
Going into 2026, what do we now know about glaucoma that we didn’t a year ago? The last quarter of 2025 brought on new clinical data and trial updates for the leading cause of irreversible blindness. In case you missed it, here are the top stories that wrapped up last year.
Related to this article
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier time points.
A wet AMD biosimilar approval leads this week’s recap, plus Medicare pay updates and tips to avoid burnout and losing patients.
MyoSpectrumNet pulls 3 public fundus datasets into 1 multi-output framework. Screening and grading accuracy held up against dedicated models.
ODs face a $32.63 Medicare conversion factor in 2027, plus 80% payment for the lower-cost service when an E/M visit and 0-day procedure share a date.
Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.
Christopher Browning, OD, and Nicholas Garn, OD, now offer cataract surgery and refractive lens exchange in their own practices.
According to Raphael Rostenne, CTO of EyeCarePro, "anything that takes time" has the potential to frustrate patients, especially before they're in a practitioner's chair.
Advertisement
Advertisement